Inhibitory Effect Of Cyclic AMP Research Articles

The Lack of Adenylyl Cyclase 1 Impairs the Inhibitory Effects of cyclic AMP on Cell Migration and Proliferation in Pancreatic Cancer

The Lack of Adenylyl Cyclase 1 Impairs the Inhibitory Effects of cyclic AMP on Cell Migration and Proliferation in Pancreatic Cancer

Platelet aggregation pathway

Platelet activation and coagulation normally do not occur in an intact blood vessel. After blood vessel wall injury, platelet plug formation is initiated by the adherence of the platelets to subendothelial collagen [1,2]. In high shear arterial blood, platelets are first slowed down from their blood flow velocity by interacting with the collagen-bound von Willebrand factor and are subsequently stopped by binding directly to the collagen by their glycoprotein (GP) receptor complex [2,3]. The activation of these collagen receptors on platelets after their binding to the collagen activates phospholipase C-mediated cascades (Fig. 1) [1–3]. This results in the mobilization of calcium from the dense tubular system [4,5]. An increase in intracellular calcium is associated with the activation of several kinases necessary for morphologic change, the presentation of the procoagulant surface, the secretion of platelet granular content, the activation of GPs, and the activation of phospholipase A2 (see Fig. 1) [2,5–7]. The presentation of the procoagulant surface results in the colocalization of different coagulation factors on the surface of the activated platelet, which triggers a series of zymogen conversions, resulting in the release of active thrombin from prothrombin [8]. Adenosine diphosphate (ADP), adenosine triphosphate, and serotonin are released from the dense platelet granule. Activated phospholipase A2 enzymes release arachidonic acid (AA) by the cleaving of fatty acids, especially phosphatidylcholine and phosphatidylethanolamine, at their sn-2 position [9–11]. AA is a precursor for thromboxane A2 (TBXA2) synthesis. In the first step in platelets, prostaglandin (PG)-endoperoxide synthase 1 (PTGS1; also known as cyclooxygenase 1) catalyzes the transformation of AA into cyclic endoperoxide PG G2 and H2 [9]. In platelets, PGG2 and PGH2 are then mainly converted by TBXA synthase into TBXA2 [9]. Fig. 1 Effects of antiplatelet drugs in platelet aggregation pathway. (PA154444041; http://www.pharmgkb.org/do/serve?objId=PA154444041o cAMP, cyclic AMP; GNAS, guanine nucleotide binding protein a s; IP3, inositol ... The mechanism of action of aspirin is the inhibition of PTGS1, thereby preventing the production of PGs and, particularly in platelets, inhibiting TBXA2 production [10–12]. In ex vivo platelet aggregation testing, aspirin affects predominantly AA-stimulated platelet aggregation through a direct pathway, and also collagen-stimulated platelet aggregation through indirect pathways. A review by Lopez Farre et al. [12] discusses further mechanisms associated with platelet response to aspirin. The processes described above result in the local accumulation of molecules such as thrombin, TBXA2, and ADP, which are important for the further recruitment of platelets and the amplification of activation signals as described above. The secreted agonists activate their respective G protein-coupled receptors: coagulation factor II (thrombin) receptors (F2R also known as protease-activated receptor 1; F2RL3 also known as protease-activated receptor 4), TBXA2 receptor (TBXA2R), and ADP receptors (P2RY1 and P2RY12) [10,11,13–15]. The P2RY12 receptor couples to Gi, and when activated by ADP, inhibits adenylate cyclase [16]. This interaction counteracts the stimulation of cyclic AMP formation by endothelial-derived PGs, which alleviates the inhibitory effect of cyclic AMP on inositol 1,4,5-trisphosphate-mediated calcium release [14,16–20]. P2RY12 has a major role in arterial thrombosis and pharmacologic targeting of this receptor, which is an important strategy in the treatment of cardiovascular diseases [21]. Thienopyridines (ticlopidine, clopidogrel, prasugrel), a class of oral anti-platelet agents, permanently inhibit P2RY12 signaling by irreversibly binding the receptor and blocking ADP-induced platelet activation and aggregation [22]. F2R, TBXA2R, and P2RY1 couple to Gq-phospholipase C–inositol 1,4,5-trisphosphate–Ca2+ pathway, inducing shape change and platelet aggregation [14,23,24]. In addition, receptor signaling by G12/13 (F2R; TBXA2R) contributes to morphologic changes through the activation of kinases [23,24]. Platelet adhesion, cytoskeletal reorganization, secretion, and amplification loops are all different steps toward the formation of a platelet plug. These cascades finally result in the activation of the fibrinogen receptor (GPIIb/GPIIIa) expressed on platelet cells [14,25,26]. This activation results in the exposure of the binding sites for fibrinogen, which are not available in inactive platelets. The binding of fibrinogen results in the linkage of the activated platelets through fibrinogen bridges, thereby mediating aggregation [3]. The inhibition of this receptor by GPIIb/GPIIIa inhibitors blocks platelet aggregation induced by any agonist [27,28]. The individual platelet response is variable because of polymorphisms in genes involved in the activation and aggregation of platelets, in conjunction with environmental factors, and contributes to diseases such as arterial thrombosis ([29–33], and http://www.bloodomics.org/web/). In addition to the variation in platelet physiology, platelet sensitivity to drugs targeting platelet activation and aggregation is also influenced by gene polymorphisms and clinical and environmental variables [29,31,34].

Ca2+-independent, inhibitory effects of cyclic AMP on Ca2+ regulation of phosphoinositide 3-kinase C2α, Rho and myosin phosphatase in vascular smooth muscle

Ca2+-independent, inhibitory effects of cyclic AMP on Ca2+ regulation of phosphoinositide 3-kinase C2α, Rho and myosin phosphatase in vascular smooth muscle

T cell receptor induced intracellular redistribution of type I protein kinase A

The productive activation of CD4(+) T lymphocytes, leading to proliferation and cytokine secretion, requires precise temporal regulation of intracellular cyclic AMP concentrations. The major effector molecule activated by cyclic AMP in mammalian cells is the cyclic AMP-dependent protein kinase A (PKA). The type I PKA isozyme mediates the inhibitory effects of cyclic AMP on T-cell activation. Using laser scanning confocal microscopy, we demonstrated that the regulation of PKA type I activity involves spatial redistribution of PKA type I molecules following T-cell receptor (TCR) stimulation. In resting T cells, PKA type I was located in membrane proximal regions and distributed equally across the cell. Shortly after antigen engagement, T cells and antigen-presenting cells formed an area of intense contact, known as the immunological synapse. TCR concentrated at the synapse, whereas PKA type I molecules redistributed to the opposite cell pole within 10 min after T-cell stimulation. Type I PKA redistribution was solely dependent on TCR signalling, because we observed the same temporal and spatial distribution after antibody-mediated cross-linking of the TCR-associated CD3 complex. Segregation of TCR and PKA type I molecules was maintained for at least 20 min. Thirty minutes after stimulation, PKA type I partially colocalized with the TCR. After 60 min, PKA type I distribution again approached the resting state. Considering that initial TCR signals lead to increases in intracellular cyclic AMP, PKA type I molecules may be targeted towards localized cyclic AMP accumulations or transported away from these areas, depending on the requirements of the cellular response.

Chronic terbutaline treatment desensitizes beta-adrenergic inhibition of lymphocyte activation in healthy volunteers.

1. A substantial body of evidence has accumulated that beta-adrenoceptor mediated increases in human lymphocyte cyclic AMP can inhibit activation of resting lymphocytes. The aim of this study was to determine whether this effect might desensitize during chronic beta-adrenoceptor agonist treatment. We assessed the effects of 2 weeks treatment with the beta 2-adrenoceptor agonist terbutaline (3 x 5 mg day-1 p.o.) on isoprenaline-induced inhibition of concanavalin A-evoked lymphocyte activation in nine healthy male volunteers. Lymphocyte activation was determined by [3H]-thymidine incorporation (as a measure of proliferation), and inositol phosphate formation was assessed in [3H]-myo-inositol prelabelled lymphocytes in the presence of 10 mM LiCl. 2. Terbutaline treatment caused a significant reduction in isoprenaline (1 nM-10 microM)-induced increases in lymphocyte cyclic AMP content; the maximal increase was 14 +/- 3 pmol/10(6) cells before and 7 +/- 2 pmol/10(6) cells (n = 9, P < 0.05) after terbutaline treatment. 3. The mitogen concanavalin A (Con A, 1-32 micrograms ml-1)-induced increase in inositol phosphate formation was significantly enhanced after terbutaline treatment (max. increase before treatment: 255 +/- 25% above basal; after treatment 453 +/- 16% above basal; n = 9, P < 0.001), while isoprenaline (1 nM-10 microM)-induced inhibition of Con A (16 micrograms ml-1)-evoked increases in inositol phosphate formation was significantly reduced after the terbutaline treatment (max. inhibition before treatment: 22 +/- 4%; after treatment 9 +/- 1%, n = 9, P < 0.01). 4. Con A (1.25-10 micrograms ml-1)-induced increases in [3H]-thymidine incorporation into the lymphocytes (as a measure of proliferation) was not affected by the terbutaline treatment. On the other hand, isoprenaline (1 nM-1 microM)-induced inhibition of Con A (5 micrograms ml-1)-evoked lymphocyte proliferation (max. inhibition: 33 +/- 7%, n = 9) was almost completely abolished after the terbutaline treatment. 5. We conclude that chronic treatment with terbutaline desensitizes lymphocyte beta 2-adrenoceptors and, therefore, the inhibitory effect of cyclic AMP on lymphocyte activation.

The effect of extracellular cyclic AMP on differentiation inducing factor (DIF)-dependant prestalk cell gene expression in monolayers of Dictyostelium is complex

Abstract An earlier finding that the ecmA and ecmB prestalk cell specific genes exhibited very different responses to cyclic AMP prompted the suggestion that cyclic AMP might act as the major spatial regulator of the prestalk cell developmental pattern in Dictyostelium. A more detailed kinetic analysis in monolayers of Dictyostelium has revealed that cyclic AMP inhibits the rate of expression of all three differentiation inducing factor (DIF) inducible genes, ecmA, ecmB and pDd26. After prolonged incubation, however, cyclic AMP enhances the levels of both ecmA and ecmB mRNAs, and nuclear run-on experiments suggest that cyclic AMP inhibits the degradation of both mRNA species. This complex response to cyclic AMP can explain the differential effects reported previously. Thus depending upon the experimental conditions, cyclic AMP can either enhance or reduce the apparent steady state level of a specific mRNA species. These results are not compatible with the earlier proposal that cyclic AMP is a spatial regulator of the prestalk developmental pattern. Although ecmA and ecmB accumulate rapidly in response to DIF, there is a lag in the accumulation of pDd26 mRNA and the induction requires protein synthesis. These results suggest that pDd26 transcription requires the accumulation of an additional factor(s). Inhibition of pDd26 mRNA accumulation by cyclic AMP also occurs during the lag period, suggesting the possibility that cyclic AMP inhibits the accumulation of the, as yet, unknown factor. The inhibitory effect of cyclic AMP on pDd26 gene expression is unaffected by caffeine, suggesting that inhibition does not involve adenylate cyclase activation. Finally the expression of pDd26 in the absence of cyclic AMP is unaffected by caffeine, suggesting that the inhibitory effect of cyclic AMP on stalk cell formation is not mediated at the level of pDd26 gene expression.

The inhibitory action of cyclic AMP on responses to carbachol dependent on calcium stores in rat gastric smooth muscle.

1. The effects of cyclic AMP on contraction and Ca(2+)-activated K+ currents induced by carbachol (CCh), caffeine and inositol 1,4,5-trisphosphate (InsP3) were examined in intact and skinned smooth muscle fibres and in whole-cell voltage-clamped smooth muscle cells of the rat stomach. Intracellular Ca2+ level, [Ca2+]i, was monitored in intact muscle fibres loaded with Fura-2. 2. In intact muscle fibres, dibutyryl cyclic AMP, 8-bromo-cyclic AMP and forskolin inhibited a phasic contraction induced by CCh (100 microM) much more extensively than that induced by caffeine (30 mM) in Ca(2+)-free solution containing 2 mM-EGTA. A rise in [Ca2+]i evoked by CCh was also reduced by dibutyryl cyclic AMP. 3. In skinned muscle fibres, InsP3 (40 microM) produced a contraction of amplitude similar to that evoked by caffeine (30 mM) in Ca(2+)-free solution containing 0.05 mM-EGTA. Cyclic AMP suppressed the InsP3-induced contraction to a much greater extent than that induced by caffeine. 4. In cells voltage-clamped at 0 mV, CCh (100 microM) evoked a transient Ca(2+)-activated outward K+ current in 61% of cells tested. After wash-out of CCh, caffeine (10 mM) evoked a similar K+ current in all cells. In cells loaded with cyclic AMP (100 microM), the percentage of cells responding to CCh was reduced to 26% and the magnitude of current response tended to decrease. Cyclic AMP caused a small increase in the caffeine-induced K+ current. 5. An outward current was elicited immediately after the patch membrane was ruptured at a holding potential of 0 mV, using a patch pipette containing InsP3 (40 microM), in 76% of cells tested. In cells treated with dibutyryl cyclic AMP, the percentage of cells responding to InsP3 was reduced to 50% and the magnitude of current response tended to decrease. 6. In intact muscle fibres loaded with Fura-2, the relationship between [Ca2+]i and tension development shifted to the right in the presence of dibutyryl cyclic AMP. In skinned muscle fibres, cyclic AMP shifted the pCa-tension relation to the right, suggesting that cyclic AMP inhibits the contractile machinery directly. 7. These results suggest that the inhibitory effect of cyclic AMP on muscarinic receptors mediating both the contraction and the Ca(2+)-activated K+ current, is partly due to the inhibition of InsP3-induced Ca2+ release from intracellular stores in rat gastric smooth muscle cells.

The inhibitory effects of cyclic AMP on contractile and current responses to carbachol in gastric smooth muscle cells of the rat

The inhibitory effects of cyclic AMP on contractile and current responses to carbachol in gastric smooth muscle cells of the rat

Cyclic AMP-elevating agents block chemoattractant activation of diradylglycerol generation by inhibiting phospholipase D activation

Agents which elevate cellular cAMP (prostaglandin E2, theophylline, and forskolin) or mimic cAMP action (dibutyryl cAMP) are known to inhibit human neutrophil activation (superoxide generation and secretion) by receptor-linked agonists such as formyl-methionyl-leucyl-phenylalanine (fMLP). Herein, we show that these agents also markedly inhibit fMLP-stimulated diradylglycerol generation (assayed by mass methods). The magnitude of inhibition correlated with the ability of a given agent or combination of agents to elevate cAMP. Both 1,2-diacylglycerol and 1-O-alkyl,2-acyl glycerol generation were affected. Effects on the latter species, as well as a lack of effect on fMLP-stimulated inositol phosphate release, implied that cAMP affected diradylglycerol generation from a source other than phospholipase C-dependent phosphoinositide hydrolysis, since phosphatidylinositols do not contain appreciable quantities of the 1-O-alkyl linkage. In cells in which the phosphatidylcholine pool was prelabeled using 1-O-[3H]octadecyl-2-lyso-sn-glycero-3-phosphocholine, prostaglandin E2 plus theophylline inhibited the fMLP-activated rapid generation of [3H]phosphatidic acid and its subsequent conversion to [3H]diradylglycerol, implying an effect at the level of phospholipase D. In the presence of ethanol, the fMLP-activated transphosphatidylation of [3H]phosphatidylcholine to generate [3H]phosphatidylethanol (a phospholipase D-dependent reaction) was also markedly inhibited. In contrast, when phorbol 12-myristate 13-acetate was used to activate cells, cAMP-related agents had no effect on phospholipase D activity, diradylglycerol generation, or superoxide generation. The data indicate an inhibitory effect of cyclic AMP on receptor-mediated phospholipase D activation at a site proximal to phospholipase D (e.g., the receptor or G protein). These studies provide a new example of "cross-talk" among signal transduction systems.

Demonstration of maturation-promoting and- inhibiting activities in mouse oocytes

The microinjection of cytoplasm from mature mouse oocytes into immature mouse oocytes induced the resumption of meiosis in the presence of 100 micrograms/ml dibutyryl cyclic AMP or 100 microM 3-isobutyl-1-methylxanthine. The volume of cytoplasm injected was critical to bringing about this maturation-promoting activity in mouse oocytes, and 20 pl of cytoplasm seems to be required to overcome the inhibitory effect of cyclic AMP on oocyte maturation. Furthermore, it was demonstrated that the microinjection of cytoplasm from immature mouse oocytes into immature mouse oocytes augmented the inhibitory effect of cyclic AMP on the resumption of meiosis. These results suggest that the appearance and disappearance of maturation-promoting and -inhibiting activities appear to be dependent on the meiotic stages in the mouse oocytes.

The role of cyclic AMP and its protein kinase in mediating acetylcholine release and the action of adenosine at frog motor nerve endings

1. The importance of adenosine 3':5'-cyclic monophosphate (cyclic AMP) and its protein kinase (protein kinase A, PKA) in promoting acetylcholine (ACh) release was studied at frog motor nerve endings. The effects of cyclic AMP-dependent protein phosphorylation on the action of adenosine receptor agonists were also investigated. 2. Cyclic AMP was delivered to a local region of the cytoplasm just beneath the plasma membrane of motor nerve endings using phospholipid vesicles (liposomes) as a vehicle. Cyclic AMP in liposomes produced a parallel reduction in the mean level of evoked ACh release (m) and spontaneous ACh release (miniature endplate potential frequency; m.e.p.p.f) in most experiments. These inhibitory effects of cyclic AMP on quantal ACh release resemble the action of adenosine. 3. The effects of global increases in cytoplasmic cyclic AMP concentrations using lipophilic cyclic AMP analogues were generally different from those observed with cyclic AMP. 8-(4-Chlorophenylthio) cyclic AMP (CPT cyclic AMP) produced approximately two fold increases in m and m.e.p.p.f. Dibutyryl cyclic AMP (db cyclic AMP) also increased m and m.e.p.p.f, with the effect on m being smaller and more variable. 4. All three cyclic AMP analogues reduced the effects of adenosine receptor agonists on spontaneous and evoked ACh release. 5. The roles of protein phosphorylation in mediating ACh release and the inhibitory effects of adenosine were studied with the protein kinase inhibitor H7. H7 (30-100 microM) produced no consistent effect on evoked or spontaneous ACh release. At these concentrations, however, H7 exerted an unfortunate inhibitory action on the nicotinic ACh receptor/ion channel. 6. H7 prevented the increases in spontaneous ACh release produced by CPT cyclic AMP (250 microM). Thus H7 is likely to inhibit PK A in frog motor nerve endings. 7. H7 did not alter the inhibitory effect of adenosine on evoked and spontaneous ACh release. 8. The results suggest: (i) that the adenylyl cyclase-cyclic AMP-PK A system is compartmentalized within the motor nerve terminal, (ii) that phosphorylation does not play a major role in ACh release and (iii) the cyclic AMP-PK A system modulates rather than mediates the inhibitory effects of adenosine.

Vasoconstrictor responses of rat tail artery to sympathetic nerve stimulation contain a component due to activation of postjunctional β- or α2-adrenoceptors

The role of α 1-, α 2- and β-adrenoceptors in vasoconstrictor responses to sympathetic nerve stimulation was investigated in perfused proximal segments of rat tail artery by using selective blocking drugs. Prazosin (1 nM) markedly reduced the responses but idazoxan (100 nM) did not, and propranolol (1 μM) significantly enhanced them, indicating that the vasoconstriction was due to activation of α 1-adrenoceptors and that it was partly counteracted by a vasodilator component due to activation of β-adrenoceptors. In the presence of propranolol, idazoxan or reduction of the concentration of Ca 2+ in the perfusing solution from 2.5 to 0.63 mM significantly reduced responses to sympathetic nerve stimulation, indicating that a component of the vasoconstrictor response was due to activation of α 2-adrenoceptors. Forskolin, which increases cyclic AMP levels independently of β-adrenoceptors, reduced responses to sympathetic nerve stimulation to a greater extent in the presence than in the absence of propranolol and this effect was additive with that of prazosin but not idazoxan. It is concluded that activation of β-adrenoceptors inhibits the component of responses to sympathetic nerve stimulation due to activation of α 2-adrenoceptors because of an inhibitory effect of cyclic AMP on Ca 2+ channels linked to α 2-adrenoceptors.

Inhibitory effect of cyclic AMP on phorbol ester-stimulated production of reactive oxygen metabolites in rat glomeruli

Studies were conducted to investigate cross-talk between protein kinase C (PKC) and cyclic AMP (cAMP) pathways using rat glomeruli (Glm). Phorbol 12-myristate 13-acetate (PMA), a PKC activator, stimulated production of reactive oxygen metabolites (ROM) in Glm. Forskolin and dibutyryl cAMP (Bt 2cAMP) inhibited production of ROM dose-dependently. In the presence of both Bt 2cAMP and 3-isobutyl-1-methylxanthine (IBMX) an additive effect was observed. Forskolin at 10 −4 M inhibited translocation of PKC from the cytosol to the membrane. These results demonstrate that cAMP-mediated inhibition can occur at a step distal to PKC activation.

O-259 - Comparison of inhibitory effects of cyclic AMP and cyclic GMP on platelet activation induced by thromboxane A2-rcceptor stimulation

O-259 - Comparison of inhibitory effects of cyclic AMP and cyclic GMP on platelet activation induced by thromboxane A2-rcceptor stimulation

The inhibitory effect of cyclic AMP on phosphatidylinositol kinase is not mediated by the cAMP dependent protein kinase.

Addition of cAMP to cells has been shown to inhibit phosphatidylinositol (PI) metabolism. cAMP has been reported to inhibit an enzyme in this pathway, PI kinase and it has been suggested that this inhibition is due to phosphorylation of PI kinase by the cAMP dependent protein kinase (PKA). In the present study we directly investigated if the inhibitory effect of cAMP was mediated by PKA. In membranes derived from murine hepatocytes we found that cAMP inhibited PI kinase but other adenine derivatives were more potent inhibitors. Moreover, it was found that the effects of the derivatives were unlikely to be due secondarily to the production of cAMP via their interaction with adenosine receptors. Through studies employing an inhibitor of PKA, mutant cells lacking PKA, and addition of purified catalytic subunit of PKA, we found that the inhibitory effect of cAMP was not mediated by PKA. In addition, the inhibitory effect of cAMP and adenosine was retained upon partial purification of PI kinase. Pulse chase experiments affirmed that the inhibitory effect was not due to breakdown of PI but rather to inhibition of its synthesis. We conclude that the inhibitory effect of cAMP and related compounds on PI kinase is not mediated by PKA dependent phosphorylation but rather appears to be a direct effect of these agents.

Interrelated calcium ion and cyclic AMP inhibition of placental lactogen secretion by cultured human term trophoblast

Calcium ion has been shown to have a negative regulatory effect on the secretion of human placental lactogen (hPL). We report an inhibitory effect of cyclic AMP on hPL secretion in a model system of cultured human term trophoblast. Similar results were obtained by modulation of cyclic AMP-phosphodiesterase. The effects of ionophore A23187 and cyclic AMP were non-additive. In searching for the sequence of the common pathway, we found that the ionophore A23187 reduced cyclic AMP concentration and that the inhibitory effect of cyclic AMP was abolished by verapamil, a calcium channel blocker, and by trifluoperazine, a calcium-calmodulin inhibitor. Cyclic AMP seems to mobilize intracellular calcium, and the latter, by way of a calcium-calmodulin complex, modulates the secretion of hPL.

The Relationship Between Intracellular Cyclic AMP Concentrations and the In Vitro Growth of Macrophages

The addition of cholera toxin, prostaglandins, or one of a series of xanthine phosphodiesterase inhibitors to bone marrow-derived macrophages maintained in liquid culture caused a dose-dependent decrease in colony formation measured 7-10 days following seeding. The growth inhibitory effects of xanthines were in the same order of potency (caffeine less than theophylline less than isobutylmethylxanthine) as their reported ability to inhibit cyclic AMP phosphodiesterase. The relationship between the magnitude of the increases in intracellular concentrations of cyclic AMP observed following the addition of the drugs and the degree of growth inhibition was complex. Combinations of cholera toxin and phosphodiesterase inhibitors caused synergistic elevations in cyclic AMP levels after a lag of approximately 3 days. However, the growth rate was decreased immediately following the addition of the combination of drugs, and thus seemed to be independent of the nucleotide levels. A cyclic AMP-resistant variant of a cloned nontransformed macrophage cell line was found to be also resistant to the growth inhibitory actions of both cholera toxin and prostaglandins. However, resistance to the inhibitory effects of cyclic AMP did not render the cells resistant to a xanthine-induced growth inhibition.

Stage-Specific Inhibitory Effect of Cyclic AMP on Asexual Maturation and Gametocyte Formation of Plasmodium falciparum

The effect of cyclic AMP on asexual maturation and gametocyte formation of Plasmodium falciparum grown in vitro was examined over a wide range of concentrations. Cyclic AMP inhibited both processes in a stage-specific manner. Asexual maturation was inhibited from shortly after parasite entry into the red cell through the ring stage. However, trophozoites and schizonts matured normally in the presence of cyclic AMP and produced infectious merozoites. Gametocyte formation was inhibited by 95% when 1.0 mM cyclic AMP was added to synchronously growing parasites in the ring stage of development but was only inhibited by 15% when added in the trophozoite or schizont stages. Cyclic AMP was not found to increase gametocyte formation over a wide range of concentrations.

Inhibition of hepatoma cell growth by analogs of adenosine and cyclic AMP and the influence of enzymes in mammalian sera.

The following evidence suggests that inhibition of hepatoma cell (HTC) growth by cyclic nucleotides is an adenosine-like effect that is greatly modified by the type and treatment of serum used in the culture medium and is probably not mediated by cyclic AMP-dependent protein kinase: 1) Heating serum reduces its phosphodiesterase content, thereby slowing metabolism of cyclic AMP and reducing the inhibition of HTC cell growth by cyclic AMP; 2) Using medium that contains phosphodiesterase but lacks adenosine deaminase causes adenosine to accumulate from cyclic AMP and increases the toxicity of cyclic AMP; 3) Uridine or cytidine reverses the growth inhibition caused by adenosine, 5'-AMP or cyclic AMP; 4) adenosine, 5'-AMP and N6-(delta 2-isopentenyl) adenosine are more toxic for HTC cells than is cyclic AMP, and N6,O2-dibutyryl cyclic AMP is not toxic; and 5) N6,O2'-dibutyryl cyclic AMP inhibits growth of Reuber H35 cells, but uridine prevents this inhibition of growth. We conclude that most, if not all, of the inhibitory effects of cyclic AMP and N6,O2'-dibutyryl cyclic AMP on HTc and Reuber H35 hepatoma cell growth are due to the generation of toxic metabolites.

Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction.

1 Cyclic adenosine 3',5'-monophosphate (cyclic AMP)- and cyclic guanosine 3',5'-monophosphate (cyclic GMP)-phosphodiesterase activities from rat lung were selectively inhibited by ZK 62711 and M & B 22948, respectively. Theophylline and papaverine inhibited both activities. 2 Rat lung strips contracted by carbachol were relaxed by 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 26711, EC25 = 7 x 10(-8)M) and 2-O-propoxyphenyl-8-azapurin-6-one (M & B 22948, EC25 = 5 x 10(-7)M) indicating relaxant properties of both cyclic AMP and cyclic GMP. 3 The antigen-induced histamine release from human basophils was inhibited by ZK 62711 (IC25 = 8 x 10(-7)M), whereas M & B 22948 had no effect. On the contrary, the release from rat mast cells was inhibited by M & B 22948 (IC25 = 10(-6)M), while ZK 62711 had no effect. 4 These data show an inhibitory effect of cyclic AMP on histamine release to be involved with basophils, whereas cyclic GMP is predominantly involved with mast cells. Is is suggested that the antianaphylactic properties of cyclic nucleotide phosphodiesterase inhibitors are mainly linked to the increase of cyclic GMP.